<DOC>
	<DOCNO>NCT00005633</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether active specific immunization comprise tyrosinase gp100:209-217 ( gp100 ) peptide fuse OVA BiP peptide heat shock protein 70 ( HSP70 ) induce immunity tyrosinase gp100 HLA-A2 positive patient stage III IV melanoma . II . Determine low optimally immunogenic dose tyrosinase gp100 patient . III . Determine tolerability regimen patient . OUTLINE : This dose escalation study tyrosinase gp100:209-217 antigen ( gp100 ) . Patients receive vaccination comprise tyrosinase gp100 fuse OVA BiP peptide heat shock protein 70 ( HSP70 ) subcutaneously week 0 , 1 , 2 , 6 , 18 total 5 vaccination absence disease progression unacceptable toxicity . Cohorts 9 patient receive escalate dos tyrosinase gp100 low optimally immunogenic dose determine . The low optimally immunogenic dose define dose 4 9 patient demonstrate T-cell response . PROJECTED ACCRUAL : A total 27 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV melanoma remission 252 week surgical resection OR minimally resectable HLAA2 positive Patients candidate potentially curative surgery eligible surgery PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2.5 mg/dL AST le 74 Units/L LDH le 400 Units/L Alkaline phosphatase great 1.5 time upper limit normal Renal : Not specify Pulmonary : No evidence disease chest xray chest CT scan If pulmonary function test abnormal , abdominal CT scan must perform Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No high risk malignancy within past 2 year except basal cell squamous cell skin cancer carcinoma situ cervix No medical condition would preclude compliance immunologic response No new metastasis study require chemotherapy radiotherapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy Endocrine therapy : No corticosteroid interval 1 week prior immunization 2 week immunization Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No antiinflammatory agent ( e.g. , aspirin ) nonsteroidal antiinflammatory drug interval 1 week prior immunization 2 week immunization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>